Maynard Um
-
-
-
-
-
-
-
Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
-
-
-
-
-
-
-
Lucid Diagnostics Inc (LUCD) PT Raised to $7.75 at Ascendiant Capital
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD)
-
-
-
-
-
-
-
Lucid Diagnostics Inc (LUCD) Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard Esophageal DNA Test
-
-
-
-
-
-
-
Lucid Diagnostics (LUCD) Announces Record Quarterly EsoGuard Test Volume
-
-
-
-
-
-
-
PAVmed (PAVM) Announces Efforts to Regain Nasdaq Compliance
-
-
-
-
-
-
-
Lucid Diagnostics (LUCD) Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuardĀ® Esophageal Precancer Testing
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

